Progressive Care Inc (fka RXMD)

[Jimmy Quick]

CMON BENCHMARK! GET TO WORK AND DOWN TO BUSINESS
THE SOONER THE BETTER THEY GET INVOLVED, I fully welcome those transactions and the expansion that will follow and I hold millions of shares. The last sentence of this post is “KEY”

Them involved spells "IN THE MONEY" for me.
Look at PillPack history and the Investment that was put into them.

TJ Parker, the son of a Concord, New Hampshire, pharmacist couple, co-founded PillPack several years ago. He told USA TODAY in September 2015 the company already had $20 million in annual revenue at the time.

Article September 6, 2016
PillPack Is Raising More Money to Take On Pharmacies
Pat Greenhouse — Boston Globe via Getty Images
By Dan Primack

Online pharmacy startup PillPack is raising new venture capital funding at around a $330 million pre-money valuation, Fortune has learned.

The Somerville, Mass.-based company on Tuesday disclosed via an SEC filing that it already has secured $31.1 million of a $40 million round, but multiple sources say that PillPack’s board has discussed increasing the overall raise to $50 million because of intense investor interest.

The Series D deal would represent an “up round” for PillPack, which raised $50 million in July 2015 at a pre-money valuation of nearly $240 million. Astral Capital, a new Boston-based venture firm led by former Accomplice partner Jon Karlen, is among the new investors already signed on. Return backers include Accomplice, Accel Partners, Charles River Ventures, and Sherpa Capital.

WE KNOW THE REST OF THE AMAZON PILLPACK STORY, expanded to 100 million annual revenues in 2017 and bought out by Amazon for $1 BILLION.

So when Ms. Mars talks about expansion through BENCHMARK below, it gets me excited CMON BABY!

Stuart Smith
Well, very good. Let's talk about - can you talk about Benchmark and how they factor into the top a nice growth agenda?

Shital Mars
So we were approached by Benchmark about doing a capital raise and we worked with them and we agreed to $10 million capital raise and now we're working around the structure of that. How would it take place, what kind of materials and due diligence, we're in that process. The purpose of working with Benchmark and the amount of money that we think is necessary is all for growth and expansion. We want to be a NASDAQ company that makes sense. We want to be a company that's really changing the face of pharmacy, changing the face of healthcare and while we are growing and we are having organic growth and we are increasing our prescription count to really make a difference on this growth, to really accelerate this growth we need real capital and so we believe that Benchmark is going to be able to provide this and provide it with investors that are friendly, that understand our market, understand our shareholder base, that are looking to - that aren't toxic in any way. We want to make sure that we're working with a company that really gets the benefit of PharmCo, of Progressive Care and the healthcare vision that we present. We chose Benchmarks for a couple of different reasons, one is their integrity and visibility, so we know that they have a large following, we know that they have institutional analyst coverage, so we know that once we do our capital raise that they will be able to provide that coverage and be able to provide that visibility for the stock afterwards and to that point a lot of us are familiar with their work on the CNBC, they are - they do have an analyst that does speak on that network from time to time and they do –they are referred to significantly in the Wall Street Capital Market industry. So we wanted to really use a reputable company and hopefully they're going to be able to deliver the kind of capital raise where our shareholders are really going to see the benefits of the accelerated growth that we can do with that expansion capital.

Stuart Smith
Well this one is similar, but you've talked about it in that response and you talked about it earlier on the update on the acquisition, but this is about different acquisitions. What are the plans for any future acquisitions?

Shital Mars
So we want to - now that we have kind of the South Florida, Greater South Florida area kind of covered which is Miami Dade, Broward, Palm Beach, Martin, St Lucie County going up that East Coast, we want to get now into the I-4 and to go over that Florida geography, we're looking at St Petersburg, Tampa, Ocala, Orlando, Kissimmee, Daytona area, Titusville area, Palm Coast all of those cities a lot of those especially Tampa, St Petersburg, Orlando, Daytona these are densely populated areas, a lot of areas where there are there are large retirement communities, where adherence is especially necessary. And the kind of services that we offer are specifically beneficial to those demographics, so we know that the next place we're going to try to go is in that in that I-4 corridor. Then if we're going up the East Coast we're going to look into Greater Jacksonville area into Georgia and those are the common sense areas that we think that we can execute on an acquisition. We're looking for targets similar to that of Touchpoint, similar in scope and in value as what Touchpoint was able to provide for us, which is that ability to have complimentary services and be able to add to our suite and portfolio of services and as well as be auditable and adaptable to the PharmCo model. The PharmCo model is what we're planning to expand and we believe that's going to drive our growth and so we want to make sure that any acquisition target we bring on board and evaluate have those synergies. So that's where we're headed next. It takes - just as you saw with Touchpoint, it can take months to execute on an acquisition, so I don't want to put out there that we're going to fully execute on an acquisition within the year, but I do believe that as we work on our expansion plans more acquisitions are part of the agenda and part of the short-term agenda, we're not talking about five years, ten years down the road, we're talking about the next 6 to 18 months of bringing more pharmacies onboard and bringing – consolidating more healthcare companies into the Progressive Care brand and model.